Elevated Circulating Lactate Levels and Widespread Expression of Its Cognate Receptor, Hydroxycarboxylic Acid Receptor 1 (HCAR1), in Ovarian Cancer

Elevated Circulating Lactate Levels and Widespread Expression of Its Cognate Receptor, Hydroxycarboxylic Acid Receptor 1 (HCAR1), in Ovarian Cancer

Background: Augmented glycolysis in cancer cells is a process required for growth and development. The Warburg effect provides evidence of increased glycolysis and lactic acid fermentation in cancer cells. The lactate end-product of glycolysis is receiving growing traction for its role as a cell sig...

Full description

Bibliographic Details
Main Authors:	Rachel Kerslake, Suzana Panfilov, Nashrah Mustafa, Marcia Hall, Ioannis Kyrou, Harpal S. Randeva, Emmanouil Karteris, Richard Godfrey
Format:	Article
Language:	English
Published:	MDPI AG 2022-12-01
Series:	Journal of Clinical Medicine
Subjects:	lactate HCAR1 biomarker ovarian cancer (OvCa) high-grade serous ovarian cancer (HGSOC) liquid biopsy
Online Access:	https://www.mdpi.com/2077-0383/12/1/217

Similar Items

Differential Regulation of Genes by the Glucogenic Hormone Asprosin in Ovarian Cancer
by: Rachel Kerslake, et al.
Published: (2022-10-01)

Transcriptional Landscape of 3D vs. 2D Ovarian Cancer Cell Models
by: Rachel Kerslake, et al.
Published: (2023-06-01)

Activation of Adrenoceptor Alpha-2 (ADRA2A) Promotes Chemosensitization to Carboplatin in Ovarian Cancer Cell Lines
by: Haya Albanna, et al.
Published: (2023-11-01)

Hormone Receptor Expression in Primary and Recurrent High-Grade Serous Ovarian Cancer and Its Implications in Early Maintenance Treatment
by: Marcus Vetter, et al.
Published: (2022-11-01)

Evaluation of Hydroxycarboxylic Acid Receptor 1 (HCAR1) as a Building Block for Genetically Encoded Extracellular Lactate Biosensors
by: Joel Wellbourne-Wood, et al.
Published: (2022-02-01)

The Uncertain Benefit of Adjuvant Chemotherapy in Advanced Low-Grade Serous Ovarian Cancer and the Pivotal Role of Surgical Cytoreduction
by: Racheal Louise Johnson, et al.
Published: (2021-12-01)

Impact of Environmentally Relevant Concentrations of Bisphenol A (BPA) on the Gene Expression Profile in an In Vitro Model of the Normal Human Ovary
by: Aeman Zahra, et al.
Published: (2022-05-01)

Cell Origins of High-Grade Serous Ovarian Cancer
by: Jaeyeon Kim, et al.
Published: (2018-11-01)

Biological and prognostic value of ETV5 in high-grade serous ovarian cancer
by: Lu Zhang, et al.
Published: (2021-11-01)

Development of a dual energy CT based model to assess response to treatment in patients with high grade serous ovarian cancer: a pilot cohort study
by: Zena Alizzi, et al.
Published: (2023-06-01)

Identification and verification of HCAR3 and INSL5 as new potential therapeutic targets of colorectal cancer
by: Xuan Yang, et al.
Published: (2021-08-01)

Human Fallopian Tube-Derived Organoids with TP53 and RAD51D Mutations Recapitulate an Early Stage High-Grade Serous Ovarian Cancer Phenotype In Vitro
by: Yilin Dai, et al.
Published: (2024-01-01)

CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma
by: Katrin Kleinmanns, et al.
Published: (2020-06-01)

Differential gene expression identifies a transcriptional regulatory network involving ER-alpha and PITX1 in invasive epithelial ovarian cancer
by: Yichao Li, et al.
Published: (2021-07-01)

Epithelial ovarian cancer is infiltrated by activated effector T cells co-expressing CD39, PD-1, TIM-3, CD137 and interacting with cancer cells and myeloid cells
by: Elena Tassi, et al.
Published: (2023-10-01)

Lactate receptor HCAR1 regulates neurogenesis and microglia activation after neonatal hypoxia-ischemia
by: Lauritz Kennedy, et al.
Published: (2022-08-01)

Exercise Regulates the Lactate Receptor HCAR1 and ERK1/2-PI3K/Akt Pathways to Promote Cerebral Angiogenesis
by: Shicun Zhang, et al.
Published: (2022-10-01)

Reduced Gonadotrophin Receptor Expression Is Associated with a More Aggressive Ovarian Cancer Phenotype
by: Janelle Cheung, et al.
Published: (2020-12-01)

Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients
by: Du-Bois Asante, et al.
Published: (2021-12-01)

Natural biased signaling of hydroxycarboxylic acid receptor 3 and G protein-coupled receptor 84
by: Anna Peters, et al.
Published: (2020-02-01)

Cancer Stem Cell Markers—Clinical Relevance and Prognostic Value in High-Grade Serous Ovarian Cancer (HGSOC) Based on The Cancer Genome Atlas Analysis
by: Natalia Iżycka, et al.
Published: (2023-08-01)

Rescue of p53 functions by in vitro‐transcribed mRNA impedes the growth of high‐grade serous ovarian cancer
by: Monika Raab, et al.
Published: (2024-01-01)

ZIP4 Is a Novel Cancer Stem Cell Marker in High-Grade Serous Ovarian Cancer
by: Qipeng Fan, et al.
Published: (2020-12-01)

Participation of L-Lactate and Its Receptor HCAR1/GPR81 in Neurovisual Development
by: Samuel Laroche, et al.
Published: (2021-06-01)

Establishment of a prognostic model for ovarian cancer based on mitochondrial metabolism-related genes
by: Chao Meng, et al.
Published: (2023-05-01)

The Transcoelomic Ecosystem and Epithelial Ovarian Cancer Dissemination
by: Sabrina J. Ritch, et al.
Published: (2022-04-01)

Ovarian cancer relies on the PDGFRβ–fibronectin axis for tumorsphere formation and metastatic spread
by: Núria Gendrau‐Sanclemente, et al.
Published: (2024-01-01)

High-grade serous carcinoma of unknown primary origin associated with STIC clinically presented as isolated inguinal lymphadenopathy: a case report
by: Paola Giancontieri, et al.
Published: (2024-02-01)

Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer
by: Inga Hoffmann, et al.
Published: (2023-10-01)

Expression of the miR-200 family in tumor tissue, plasma and urine of epithelial ovarian cancer patients in comparison to benign counterparts
by: Kalle Savolainen, et al.
Published: (2020-07-01)

Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints
by: Delphine Hudry, et al.
Published: (2022-10-01)

Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status
by: Pia Roering, et al.
Published: (2022-08-01)

Clinical value of bioelectrical properties of cancerous tissue in advanced epithelial ovarian cancer patients
by: Paula Cunnea, et al.
Published: (2018-10-01)

High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer
by: Min Li, et al.
Published: (2020-10-01)

Lactate Neuroprotection against Transient Ischemic Brain Injury in Mice Appears Independent of HCAR1 Activation
by: Lara Buscemi, et al.
Published: (2022-05-01)

Combining Mass Cytometry Data by CyTOFmerge Reveals Additional Cell Phenotypes in the Heterogeneous Ovarian Cancer Tumor Microenvironment: A Pilot Study
by: Liv Cecilie Vestrheim Thomsen, et al.
Published: (2023-10-01)

Integrated Multi-Omic Analysis Reveals Immunosuppressive Phenotype Associated with Poor Outcomes in High-Grade Serous Ovarian Cancer
by: Russell Keathley, et al.
Published: (2023-07-01)

Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells in vitro
by: Franziska Brauneck, et al.
Published: (2023-10-01)

A chemotherapy response prediction model derived from tumor-promoting B and Tregs and proinflammatory macrophages in HGSOC
by: Yue Xi, et al.
Published: (2023-07-01)

Differential Expression of RAD51AP1 in Ovarian Cancer: Effects of siRNA In Vitro
by: Alice Filipe, et al.
Published: (2022-02-01)